Sridharan Raghavan1,2,3, Theodore Warsavage1,4, Wenhui G Liu1, Katherine Raffle1, Kevin Josey1,5, David R Saxon1,6, Lawrence S Phillips7,8, Liron Caplan1,9, Jane E B Reusch1,6. 1. Medicine Service, U.S. Department of Veterans Affairs, Eastern Colorado Health Care System, Aurora, CO. 2. Division of Biomedical Informatics and Personalized Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO. 3. Colorado Cardiovascular Outcomes Research Consortium, Aurora, CO. 4. Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO. 5. Department of Biostatistics, Harvard School of Public Health, Boston, MA. 6. Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO. 7. Medicine Service, Atlanta Veterans Affairs Medical Center, Decatur, GA. 8. Department of Medicine, Emory University School of Medicine, Atlanta, GA. 9. Division of Rheumatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Abstract
OBJECTIVE: Therapeutic inertia threatens the potential long-term benefits of achieving early glycemic control after type 2 diabetes diagnosis. We evaluated temporal trends in second-line diabetes medication initiation among individuals initially treated with metformin. RESEARCH DESIGN AND METHODS: We included data from 199,042 adults with type 2 diabetes in the U.S. Department of Veterans Affairs health care system initially treated with metformin monotherapy from 2005 to 2013. We used multivariable Cox proportional hazards and linear regression to estimate associations of year of metformin monotherapy initiation with time to second-line diabetes treatment over 5 years of follow-up (primary outcome) and with hemoglobin A1c (HbA1c) at the time of second-line diabetes treatment initiation (secondary outcome). RESULTS: The cumulative 5-year incidence of second-line medication initiation declined from 47% among metformin initiators in 2005 to 36% in 2013 counterparts (P < 0.0001) despite a gradual increase in mean HbA1c at the end of follow-up (from 6.94 ± 1.28% to 7.09 ± 1.42%, Ptrend < 0.0001). In comparisons with metformin monotherapy initiators in 2005, adjusted hazard ratios for 5-year initiation of second-line diabetes treatment ranged from 0.90 (95% CI 0.87, 0.92) for 2006 metformin initiators to 0.68 (0.66, 0.70) for 2013 counterparts. Among those receiving second-line treatment within 5 years of metformin initiation, HbA1c at second-line medication initiation increased from 7.74 ± 1.66% in 2005 metformin initiators to 8.55 ± 1.92% in 2013 counterparts (Ptrend < 0.0001). CONCLUSIONS: We observed progressive delays in diabetes treatment intensification consistent with therapeutic inertia. Process-of-care interventions early in the diabetes disease course may be needed to reverse adverse temporal trends in diabetes care.
OBJECTIVE: Therapeutic inertia threatens the potential long-term benefits of achieving early glycemic control after type 2 diabetes diagnosis. We evaluated temporal trends in second-line diabetes medication initiation among individuals initially treated with metformin. RESEARCH DESIGN AND METHODS: We included data from 199,042 adults with type 2 diabetes in the U.S. Department of Veterans Affairs health care system initially treated with metformin monotherapy from 2005 to 2013. We used multivariable Cox proportional hazards and linear regression to estimate associations of year of metformin monotherapy initiation with time to second-line diabetes treatment over 5 years of follow-up (primary outcome) and with hemoglobin A1c (HbA1c) at the time of second-line diabetes treatment initiation (secondary outcome). RESULTS: The cumulative 5-year incidence of second-line medication initiation declined from 47% among metformin initiators in 2005 to 36% in 2013 counterparts (P < 0.0001) despite a gradual increase in mean HbA1c at the end of follow-up (from 6.94 ± 1.28% to 7.09 ± 1.42%, Ptrend < 0.0001). In comparisons with metformin monotherapy initiators in 2005, adjusted hazard ratios for 5-year initiation of second-line diabetes treatment ranged from 0.90 (95% CI 0.87, 0.92) for 2006 metformin initiators to 0.68 (0.66, 0.70) for 2013 counterparts. Among those receiving second-line treatment within 5 years of metformin initiation, HbA1c at second-line medication initiation increased from 7.74 ± 1.66% in 2005 metformin initiators to 8.55 ± 1.92% in 2013 counterparts (Ptrend < 0.0001). CONCLUSIONS: We observed progressive delays in diabetes treatment intensification consistent with therapeutic inertia. Process-of-care interventions early in the diabetes disease course may be needed to reverse adverse temporal trends in diabetes care.
Authors: L S Phillips; W T Branch; C B Cook; J P Doyle; I M El-Kebbi; D L Gallina; C D Miller; D C Ziemer; C S Barnes Journal: Ann Intern Med Date: 2001-11-06 Impact factor: 25.391
Authors: Amir Qaseem; Timothy J Wilt; Devan Kansagara; Carrie Horwitch; Michael J Barry; Mary Ann Forciea; Nick Fitterman; Kate Balzer; Cynthia Boyd; Linda L Humphrey; Alfonso Iorio; Jennifer Lin; Michael Maroto; Robert McLean; Reem Mustafa; Janice Tufte Journal: Ann Intern Med Date: 2018-03-06 Impact factor: 25.391
Authors: David C Ziemer; Christopher D Miller; Mary K Rhee; Joyce P Doyle; Clyde Watkins; Curtiss B Cook; Daniel L Gallina; Imad M El-Kebbi; Catherine S Barnes; Virginia G Dunbar; William T Branch; Lawrence S Phillips Journal: Diabetes Educ Date: 2005 Jul-Aug Impact factor: 2.140
Authors: William Duckworth; Carlos Abraira; Thomas Moritz; Domenic Reda; Nicholas Emanuele; Peter D Reaven; Franklin J Zieve; Jennifer Marks; Stephen N Davis; Rodney Hayward; Stuart R Warren; Steven Goldman; Madeline McCarren; Mary Ellen Vitek; William G Henderson; Grant D Huang Journal: N Engl J Med Date: 2008-12-17 Impact factor: 91.245
Authors: Ioanna Gouni-Berthold; Heiner K Berthold; Christos S Mantzoros; Michael Böhm; Wilhelm Krone Journal: Diabetes Care Date: 2008-03-28 Impact factor: 19.112